Abstract
During the last 50 years the global pandemic of obesity and associated life-threatening co-morbidities strongly promoted the development of anti-obesity pharmacotherapy. Sibutramine is an anti-obesity drug that in conjunction with lifestyle modifications reduces food intake and body weight. This may result from several effects: inhibition of presynaptic reuptake of monoaminergic neurotransmitters in the central nervous system, thereby suppressing appetite, induction of an increase in anorexigenic and a decrease in orexigenic neuropeptide secretion, induction of an increase in energy expenditure, and induction of peripheral sympathomimetic effects. The effects of sibutramine on anabolic and catabolic signals that regulate energy homeostasis in the hypothalamus are not completely understood. So, the aim of this review is to summarize the central mechanisms of action of sibutramine, responsible for its weight and food intake reducing potential. Despite being a useful drug in obesity treatment, awareness about the loss of long-term effectiveness and detrimental side effects of sibutramine has recently emerged. As a consequence, new drugs that produce safer and more persistent weight loss are currently undergoing clinical trials.
Keywords: Appetite, obesity, sibutramine, hypothalamus, weight loss, amplifying anorexigenic, type 2 diabetes
Current Neuropharmacology
Title: Sibutramine Effects on Central Mechanisms Regulating Energy Homeostasis
Volume: 10 Issue: 1
Author(s): Joao R. Araujo and Fatima Martel
Affiliation:
Keywords: Appetite, obesity, sibutramine, hypothalamus, weight loss, amplifying anorexigenic, type 2 diabetes
Abstract: During the last 50 years the global pandemic of obesity and associated life-threatening co-morbidities strongly promoted the development of anti-obesity pharmacotherapy. Sibutramine is an anti-obesity drug that in conjunction with lifestyle modifications reduces food intake and body weight. This may result from several effects: inhibition of presynaptic reuptake of monoaminergic neurotransmitters in the central nervous system, thereby suppressing appetite, induction of an increase in anorexigenic and a decrease in orexigenic neuropeptide secretion, induction of an increase in energy expenditure, and induction of peripheral sympathomimetic effects. The effects of sibutramine on anabolic and catabolic signals that regulate energy homeostasis in the hypothalamus are not completely understood. So, the aim of this review is to summarize the central mechanisms of action of sibutramine, responsible for its weight and food intake reducing potential. Despite being a useful drug in obesity treatment, awareness about the loss of long-term effectiveness and detrimental side effects of sibutramine has recently emerged. As a consequence, new drugs that produce safer and more persistent weight loss are currently undergoing clinical trials.
Export Options
About this article
Cite this article as:
R. Araujo Joao and Martel Fatima, Sibutramine Effects on Central Mechanisms Regulating Energy Homeostasis, Current Neuropharmacology 2012; 10 (1) . https://dx.doi.org/10.2174/157015912799362788
DOI https://dx.doi.org/10.2174/157015912799362788 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Development of Nitric Oxide Donors for the Treatment of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Periodontitis and Atherosclerosis, a Causal Relationship?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Metabolic Targets of Cardiac HormonesTherapeutic Anti-Cancer Effects
Current Pharmaceutical Design Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science A Review of Flavonoids from Cassia Species and their Biological Activity
Current Pharmaceutical Biotechnology Small RNAs Play Big Roles: MicroRNAs in Diabetic Wound Healing
Current Molecular Medicine Interaction Between Platelets and Cytokines - A Possible Role in the Pathogenesis of Preeclampsia
Vascular Disease Prevention (Discontinued) The Future of Angiotensin II Inhibition in Cardiovascular Medicine
Current Drug Targets - Cardiovascular & Hematological Disorders Enzymatic Processing of <i>Omega</i> 3 Long Chain Polyunsaturated Fatty Acid Oils
Current Nutrition & Food Science How to Advise Aspirin Use in Patients Who Need NSAIDs
Current Pharmaceutical Design Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Recent Patents in Plant Biotechnology: Impact on Global Health
Recent Patents on Biotechnology Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Current Vascular Pharmacology Use of Corticosteroids in Critically Ill Septic Patients: A Review of Mechanisms of Adrenal Insufficiency in Sepsis and Treatment
Current Drug Targets Anti-Inflammatory Drugs and Statins for Arterial Stiffness Reduction
Current Pharmaceutical Design Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases
Current Enzyme Inhibition Obesity and Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets HDL - Cholesterol: The New Target for Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Inflammatory Biomarkers in Chronic Kidney Disease: A Review
Recent Patents on Biomarkers Combining Diffusion-Weighted Imaging Patterns with ABCD2 Score Predicts Stroke Risk after Transient Ischemic Attack
Current Neurovascular Research